Cargando…
The treatment of refractory periorbital dermatitis
PURPOSE: Refractory periorbital dermatitis has a chronic course with exacerbations leading to discomfort and cosmetic issues, yet characterization of treatment options is limited. AIMS: The objective was to present comprehensive demographic data and medical management of a series of patients with re...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683672/ https://www.ncbi.nlm.nih.gov/pubmed/37787240 http://dx.doi.org/10.4103/IJO.IJO_2944_22 |
_version_ | 1785151247574106112 |
---|---|
author | Meer, Elana A Patel, Suraj B Herskowitz, William B A Briceño, César A |
author_facet | Meer, Elana A Patel, Suraj B Herskowitz, William B A Briceño, César A |
author_sort | Meer, Elana A |
collection | PubMed |
description | PURPOSE: Refractory periorbital dermatitis has a chronic course with exacerbations leading to discomfort and cosmetic issues, yet characterization of treatment options is limited. AIMS: The objective was to present comprehensive demographic data and medical management of a series of patients with refractory periorbital dermatitis. SETTINGS AND DESIGN: Retrospective review identified patients treated at a single institution from January 2010 to August 2020. METHODS: Descriptive analyses were performed. Demographic data and treatment history were reviewed and data including medication, use, date of use and discontinued use, reason for discontinuation (if applicable), refractory status, formulation, concentration, and dose frequency were extracted. STATISTICAL ANALYSIS USED: Descriptive analyses. RESULTS: Forty-five patients were included. The average age at first diagnosis was 60.3 years (sd 14.9). 82.2% were women and 84.4% identified as Caucasian. Triamcinolone cream was most frequently used followed by tobramycin–dexamethasone, tacrolimus, and neomycin–polymyxin–dexamethasone. Less than 30% of patients on triamcinolone were refractory. 13.3% of patients used topical hydrocortisone, with over 80% of these patients experiencing refractory episodes of persistent irritation and erythema. Most patients were refractory during initial use or the first recurrence of periorbital dermatitis flare. CONCLUSIONS: By better characterizing the diverse treatment regimens in a unique subset of refractory patients, we hope to better inform potential courses of medical management for periorbital dermatitis. |
format | Online Article Text |
id | pubmed-10683672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-106836722023-11-30 The treatment of refractory periorbital dermatitis Meer, Elana A Patel, Suraj B Herskowitz, William B A Briceño, César A Indian J Ophthalmol Original Article PURPOSE: Refractory periorbital dermatitis has a chronic course with exacerbations leading to discomfort and cosmetic issues, yet characterization of treatment options is limited. AIMS: The objective was to present comprehensive demographic data and medical management of a series of patients with refractory periorbital dermatitis. SETTINGS AND DESIGN: Retrospective review identified patients treated at a single institution from January 2010 to August 2020. METHODS: Descriptive analyses were performed. Demographic data and treatment history were reviewed and data including medication, use, date of use and discontinued use, reason for discontinuation (if applicable), refractory status, formulation, concentration, and dose frequency were extracted. STATISTICAL ANALYSIS USED: Descriptive analyses. RESULTS: Forty-five patients were included. The average age at first diagnosis was 60.3 years (sd 14.9). 82.2% were women and 84.4% identified as Caucasian. Triamcinolone cream was most frequently used followed by tobramycin–dexamethasone, tacrolimus, and neomycin–polymyxin–dexamethasone. Less than 30% of patients on triamcinolone were refractory. 13.3% of patients used topical hydrocortisone, with over 80% of these patients experiencing refractory episodes of persistent irritation and erythema. Most patients were refractory during initial use or the first recurrence of periorbital dermatitis flare. CONCLUSIONS: By better characterizing the diverse treatment regimens in a unique subset of refractory patients, we hope to better inform potential courses of medical management for periorbital dermatitis. Wolters Kluwer - Medknow 2023-10 2023-09-29 /pmc/articles/PMC10683672/ /pubmed/37787240 http://dx.doi.org/10.4103/IJO.IJO_2944_22 Text en Copyright: © 2023 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Meer, Elana A Patel, Suraj B Herskowitz, William B A Briceño, César A The treatment of refractory periorbital dermatitis |
title | The treatment of refractory periorbital dermatitis |
title_full | The treatment of refractory periorbital dermatitis |
title_fullStr | The treatment of refractory periorbital dermatitis |
title_full_unstemmed | The treatment of refractory periorbital dermatitis |
title_short | The treatment of refractory periorbital dermatitis |
title_sort | treatment of refractory periorbital dermatitis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683672/ https://www.ncbi.nlm.nih.gov/pubmed/37787240 http://dx.doi.org/10.4103/IJO.IJO_2944_22 |
work_keys_str_mv | AT meerelanaa thetreatmentofrefractoryperiorbitaldermatitis AT patelsurajb thetreatmentofrefractoryperiorbitaldermatitis AT herskowitzwilliamba thetreatmentofrefractoryperiorbitaldermatitis AT bricenocesara thetreatmentofrefractoryperiorbitaldermatitis AT meerelanaa treatmentofrefractoryperiorbitaldermatitis AT patelsurajb treatmentofrefractoryperiorbitaldermatitis AT herskowitzwilliamba treatmentofrefractoryperiorbitaldermatitis AT bricenocesara treatmentofrefractoryperiorbitaldermatitis |